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Background: Since the introduction of nucleos(t)ide analogues
(NUCs), there has been marked improvement in the care of the
patients with chronic hepatitis B, resulting in increased survival.
Adefovir dipivoxil (ADV) has shown efﬁcacy and safety in a broad
range of populations with chronic hepatitis B over 48 to 96 weeks.
This study reports the 192-week long-term efﬁcacy data with ADV
treatment in nucleoside-naive HBeAg-positive chronic hepatitis B.
Methods & Materials: Ninety-eight HBeAg-positive patients
who had never received nucleoside treatment received 192-week
ADV10mg/d therapy. All patients had serum level of HBV load
over 105copies/ml and increased serum alanine aminotransferase
(ALT) level. Based on serum ALT levels at baseline, all patients were
divided into two groups, A (48 patients with serum ALT level less
than 200U/L) and B (50 patients with ALT level more than 200U/L).
Serum HBV load was measured with quantitative real-time-PCR.
ALT activity, HBeAg, anti-HBe-antibodies, HBVDNA level in serum
were evaluated at baseline, week 12, 24, 48, 72, 96, 144, 168 and
192 and during therapy.
Results: After 24 weeks of therapy, mean reduction of HBVDNA
level, the percentage of patients with HBVDNA lower than 5 log10
copies/ml and the percentage of patients with HBVDNA level
decrease of more than 2 log10 copies/ml in group B were signif-
icantly higher than those in group A (P<0.05, respectively). At the
end of 24, 48, 96, 144 and 192 weeks, the patients in group B had
higher rates of undetectable serum HBVDNA levels and ALT nor-
malization than those in group A (46% vs 25%, 74% vs 54.2%, 88%
vs 70.8%, 90% vs 72.9%, 91.3% vs 71.8%; 52% vs 31.3%, 66% vs 43.8%,
82% vs 62.5%, 88% vs 66.7%, 93.8% vs72.5%; P<0.05, respectively).
HBeAg seroconversion rate was signiﬁcant hihger in group B than
those in group A(P<0.05). There was no evidence of adverse effect
in patients treated for up to 192 weeks.
Conclusion: Adefovir dipivoxil is an effective treatment option
for nucleoside-naive patients with HBeAg-positive chronic hepati-
tis B, especially for those with high serum ALT levels at baseline.
Adefovir dipivoxil treatment through192weekswaswell tolerated
and resulted in continued beneﬁt for patients with HBeAg-positive
chronic hepatitis B.
http://dx.doi.org/10.1016/j.ijid.2014.03.1080
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Background:HepatitisBvirus (HBV) infection is a serioushealth
problem worldwide. The pathogenesis of persistent viral infection
andhepatitis B is very complex. Bothviral factors, aswell as thehost
immune response, have been implicated in the pathogenesis and
clinical outcome of HBV infection. But the mechanism has not been
clariﬁed. We aimed to investigate the levels of macrophage migra-
tion inhibitory factor (MIF), transforming growth factor- (TGF-),
interleukin-17 (IL-17) and interleukin-10 (IL-10) and their correla-
tionwith liver disease and viral replication in patientswith chronic
HBV infection.
Methods & Materials: One hundred and thirty-eight chronic
HBV infected patients [including chronic hepatitis B (CHB), liver
cirrhosis (LC), hepatocellular carcinoma (HCC)] were enrolled the
study. 30 normal individuals were as control group. Serum levels
of MIF, TGF-, IL-17 and IL-10 were measured using an enzyme-
linked immunosorbent assay (ELISA). HBV markers were detected
with ELISA. Serum HBV DNA load was assessed with quantitative
Real-Time PCR.
Results: Chronic HBV infected patients had signiﬁcantly
increased serum levels of MIF, TGF- and IL-17, and decreased IL-
10 compared with normal individuals (p <0.01, 0.01, 0.001, 0.01,
respectively). Univariate analysis showed a similar pattern of the
parametersMIF,TGF- and IL-17were signiﬁcantly associatedwith
high viral load, presence of serum hepatitis B e antigen (HBeAg)
expression, liver disease severity, and young age at HBV infec-
